Prevalence of EGFR mutations in patients with resected stage I–III non-small cell lung cancer: results from EARLY-EGFR Latin America study
The LATAM subset shows an <i>EGFR</i>m prevalence of 39.5%. Despite American Society of Clinical Oncology guidelines recommending AT in PS IB-IIIB, only about 32% received it. Our results are important for guiding <i>EGFR</i> testing and informing treatment strategies in LATAM with recent and upcoming approvals of targeted and immunotherapy.
Authors
- Francisco Suárez (ORCID: https://orcid.org/0000-0002-4394-957X)
- Reto Huggenberger
- Adrián Puello Guerrero
- Luis Fernando Tejado Gallegos
- Herman Andrés Perroud (ORCID: https://orcid.org/0000-0002-0904-2085)
- Edgar Amorín Kajatt
- Natalia Donner (ORCID: https://orcid.org/0000-0003-4181-5102)
- Luis Gerardo García-Herreros
- Luis Corrales
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Switzerland) (CH)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/jtd-2025-904
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00